Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

Авторы: Chesney Jason A., Ribas Antoni, Long Georgina V., Kirkwood John M., Dummer Reinhard, Puzanov Igor, Hoeller Christoph, Gajewski Thomas F., Gutzmer Ralf, Rutkowski Piotr, Demidov Lev, Arenberger Petr, Shin Sang Joon, Ferrucci Pier Francesco, Haydon Andrew, Hyngstrom John, van Thienen Johannes V., Haferkamp Sebastian, Guilera Josep Malvehy, Rapoport Bernardo Leon, VanderWalde Ari, Diede Scott J., Anderson James R., Treichel Sheryl, Chan Edward L., Bhatta Sumita, Gansert Jennifer, Hodi Frank Stephen, Gogas Helen
Журнал: Journal of Clinical Oncology
Год издания: 2022
Издательство: American Society of Clinical Oncology
Местоположение издательства: United States
DOI: 10.1200/jco.22.00343
Аннотация: The combination of talimogene laherparepvec (T-VEC) and pembrolizumab previously demonstrated an acceptable safety profile and an encouraging complete response rate (CRR) in patients with advanced melanoma in a phase Ib study. We report the efficacy and safety from a phase III, randomized, double-blind, multicenter, international study of T-VEC plus pembrolizumab (T-VEC-pembrolizumab) versus placebo plus pembrolizumab (placebo-pembrolizumab) in patients with advanced melanoma.
Добавил в систему: Демидов Лев Вадимович

	ИСТИНА	Войти в систему Регистрация
	ИСТИНА ИНХС РАН
	Главная Поиск Статистика О проекте Помощь

ИСТИНА